23andMe gets FDA approval for BRCA cancer risk DNA test

The FDA has approved a 23andMe’s cancer risk test, one that provides the results directly to the consumer rather than to a doctor who would then provide their patient with info. The approval is specifically for the Personal Genome Service Genetic Health Risk (GHR) Report for the BRCA1/BRCA2 test revealing breast, prostate, and ovarian cancer risk. Early in its history, …